Browse LRRTM4

Summary
SymbolLRRTM4
Nameleucine rich repeat transmembrane neuronal 4
Aliases FLJ12568; leucine-rich repeat transmembrane neuronal 4 protein; Leucine-rich repeat transmembrane neuronal p ......
Chromosomal Location2p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Single-pass type I membrane protein Cell junction, synapse, postsynaptic cell membrane Single-pass type I membrane protein
Domain PF13855 Leucine rich repeat
Function

May play a role in the development and maintenance of the vertebrate nervous system. Exhibits strong synaptogenic activity, restricted to excitatory presynaptic differentiation (By similarity).

> Gene Ontology
 
Biological Process GO:0001933 negative regulation of protein phosphorylation
GO:0006469 negative regulation of protein kinase activity
GO:0007259 JAK-STAT cascade
GO:0033673 negative regulation of kinase activity
GO:0042326 negative regulation of phosphorylation
GO:0046425 regulation of JAK-STAT cascade
GO:0046426 negative regulation of JAK-STAT cascade
GO:0050808 synapse organization
GO:0051348 negative regulation of transferase activity
GO:0097696 STAT cascade
GO:1902532 negative regulation of intracellular signal transduction
GO:1904892 regulation of STAT cascade
GO:1904893 negative regulation of STAT cascade
Molecular Function GO:0004857 enzyme inhibitor activity
GO:0004860 protein kinase inhibitor activity
GO:0019207 kinase regulator activity
GO:0019210 kinase inhibitor activity
GO:0019887 protein kinase regulator activity
Cellular Component GO:0045211 postsynaptic membrane
GO:0097060 synaptic membrane
GO:0098794 postsynapse
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-6794361: Interactions of neurexins and neuroligins at synapses
R-HSA-112316: Neuronal System
R-HSA-6794362: Protein-protein interactions at synapses
Summary
SymbolLRRTM4
Nameleucine rich repeat transmembrane neuronal 4
Aliases FLJ12568; leucine-rich repeat transmembrane neuronal 4 protein; Leucine-rich repeat transmembrane neuronal p ......
Chromosomal Location2p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between LRRTM4 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolLRRTM4
Nameleucine rich repeat transmembrane neuronal 4
Aliases FLJ12568; leucine-rich repeat transmembrane neuronal 4 protein; Leucine-rich repeat transmembrane neuronal p ......
Chromosomal Location2p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of LRRTM4 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell logFC: -1.55; FDR: 0.04220 Resistant to T cell-mediated killing
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolLRRTM4
Nameleucine rich repeat transmembrane neuronal 4
Aliases FLJ12568; leucine-rich repeat transmembrane neuronal 4 protein; Leucine-rich repeat transmembrane neuronal p ......
Chromosomal Location2p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of LRRTM4 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.3810.386
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.4020.577
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.3740.554
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.6390.241
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.780.521
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.4590.751
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.3620.777
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-2.1560.237
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11121.5510.419
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.2030.694
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.0260.969
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.1960.54
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of LRRTM4 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277311.11.49.70.0589
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275911.11.79.40.0895
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211714.311.82.51
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)86016.7-16.70.429
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131123.19.1140.596
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.37.4-2.11
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.515.4-10.90.541
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolLRRTM4
Nameleucine rich repeat transmembrane neuronal 4
Aliases FLJ12568; leucine-rich repeat transmembrane neuronal 4 protein; Leucine-rich repeat transmembrane neuronal p ......
Chromosomal Location2p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of LRRTM4. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolLRRTM4
Nameleucine rich repeat transmembrane neuronal 4
Aliases FLJ12568; leucine-rich repeat transmembrane neuronal 4 protein; Leucine-rich repeat transmembrane neuronal p ......
Chromosomal Location2p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of LRRTM4. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by LRRTM4.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolLRRTM4
Nameleucine rich repeat transmembrane neuronal 4
Aliases FLJ12568; leucine-rich repeat transmembrane neuronal 4 protein; Leucine-rich repeat transmembrane neuronal p ......
Chromosomal Location2p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of LRRTM4. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolLRRTM4
Nameleucine rich repeat transmembrane neuronal 4
Aliases FLJ12568; leucine-rich repeat transmembrane neuronal 4 protein; Leucine-rich repeat transmembrane neuronal p ......
Chromosomal Location2p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of LRRTM4 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolLRRTM4
Nameleucine rich repeat transmembrane neuronal 4
Aliases FLJ12568; leucine-rich repeat transmembrane neuronal 4 protein; Leucine-rich repeat transmembrane neuronal p ......
Chromosomal Location2p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between LRRTM4 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolLRRTM4
Nameleucine rich repeat transmembrane neuronal 4
Aliases FLJ12568; leucine-rich repeat transmembrane neuronal 4 protein; Leucine-rich repeat transmembrane neuronal p ......
Chromosomal Location2p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting LRRTM4 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.